RxDoctor Payments Data

Regis Britto, MD

Internal Medicine · Redding, CANPI 1790824340

Payments from drug & device makers

$1,304in general payments, 2019–2025

Across 57 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$350
  • AstraZeneca$317
  • Boehringer Ingelheim$160
  • Pfizer$126
  • GSK$77
  • Johnson & Johnson$69
  • plus $205 from 7 others

What the payments were for

  • Food & beverage$1,304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,304 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$333,584
Medicare patients
888
Services billed
4,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$81,704
FarxigaDapagliflozin Propanediol45$49,643
OzempicSemaglutide26$39,529
JardianceEmpagliflozin25$39,291
JanuviaSitagliptin Phosphate24$37,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$35,695
TrulicityDulaglutide20$32,749
PremarinEstrogens, Conjugated14$8,391
Breo ElliptaFluticasone/Vilanterol12$7,084
SynthroidLevothyroxine Sodium88$6,225
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$5,881
Levothyroxine Sodium422$5,792
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$5,712
Advair HfaFluticasone Propion/Salmeterol12$5,405
Rosuvastatin Calcium247$5,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$126$90,09579 claims
AstraZenecaFarxiga$317$49,64345 claims
GSKTrelegy Ellipta, Breo Ellipta$77$42,77949 claims
Novo NordiskOzempic$350$39,52926 claims
Boehringer IngelheimJardiance$160$39,29125 claims
Lilly USA, LLCTrulicity, Humalog$20$34,12231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →